 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- || R 1541 / Roche
Clinical, Journal: Peripartum cardiomyopathy: An analysis of clinical profiles and outcomes from a tertiary care centre in southern India. (Pubmed Central) - Dec 22, 2020
The incidence of peripartum cardiomyopathy was one case per 1541 live births...Peripartum cardiomyopathy with poor left ventricular ejection fraction and shock is associated with adverse maternal outcomes, while non-severe maternal anaemia predisposes to adverse fetal outcomes. Significant left ventricular ejection fraction recovery occurred on follow-up.
- | R 1541 / Roche
Journal: Three GLI2 mutations combined potentially underlie non-syndromic cleft lip with or without cleft palate in a Chinese pedigree. (Pubmed Central) - Jun 26, 2020
Significant left ventricular ejection fraction recovery occurred on follow-up. Our results further demonstrate that GLI2 variants play a role in the pathogenesis of NSCL/P, and the three rare missense mutations combined are probably the potential disease-causing variants in this family.
- | R 1541 / Roche
Journal: High peak-power and narrow-linewidth all-fiber Raman nanosecond laser in 1.65 µm waveband. (Pubmed Central) - Apr 1, 2020
The repetition-rate and the pulse-width of the 1653.7 nm pulsed laser are 100 kHz and 31 ns, respectively. The peak power is estimated to be as high as about 30.85 W, and a 3-dB linewidth as narrow as less than 0.08 nm is achieved when the average power of 1541 nm pump is 3.1 W. The wavelength of Raman pulsed laser can be tuned from 1652.0 nm to 1654.0 nm continuously with an optical signal-to-noise ratio (OSNR) of more than 35 dB.
- | imatinib / Generic mfg.
Journal: An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. (Pubmed Central) - Feb 29, 2020
We confirmed that these SNPs could stratify the cohort of 49 patients according to the risk of developing progression under imatinib treatment. In conclusion, we identified a genetic signature of response to imatinib therapy in GIST patients able to stratify patients at low and high risk to progress, according to their genotype.
- | R 1541 / Roche
Journal: Benchmark and integration of resources for the estimation of human transcription factor activities. (Pubmed Central) - Feb 1, 2020
We assessed their coverage and found little overlap on the regulons derived from each strategy and better performance by literature-curated information followed by ChIP-seq data. We provide an integrated resource of all TF-target interactions derived through these strategies, with confidence scores, as a resource for enhanced prediction of TF activities.
- R 1541 / Roche
Mediator Complex (MED) 7 is Downregulated in High Grade Ductal Carcinoma in Situ (DCIS) (LACC West Exhibit Hall A, Poster Board Number: 23) - Jan 24, 2020 - Abstract #USCAP2020USCAP_1995;
Taken together, our data establishes MED7 H-score as a tangible tool for evaluating high grade DCIS. Further studies are underway to establish a practical cut-off value for the MED7 H-Score for high grade DCIS.
- || paclitaxel / Generic mfg.
Biomarker, Clinical, Journal, Heterogeneity: Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. (Pubmed Central) - Nov 14, 2019
With the exception of a variant in VKORC1, the present study did not find the same genetic outcome associations of other published research on pharmacogenetics variants that affect paclitaxel outcomes. This finding suggests that prior pharmacogenomics research findings may not be reproduced in the most frequently-diagnosed malignancy, lung cancer.